GvHD prophylaxis with ATG-fresenius S in allogeneic stem cell transplantation from matched unrelated donors: A randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-Fresenius S.

Trial Profile

GvHD prophylaxis with ATG-fresenius S in allogeneic stem cell transplantation from matched unrelated donors: A randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-Fresenius S.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin; Methotrexate
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ATG-F; SCT
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 26 Jun 2017 Results of 8 year follow-up published in a Neovii Biotech media release.
    • 26 Jun 2017 Results of 8-year follow-up published in the June 2017 edition of The Lancet Haematology, according to a Neovii Biotech media release.
    • 18 Jan 2016 According to a Neovii Pharmaceuticals media release, results were published in New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top